If there's one molecule that sits at the absolute center of aging biology, it's NAD+. Not because it does one important thing — because it does everything. Energy production, DNA repair, gene expression regulation, circadian rhythm, inflammatory signaling, stem cell function. NAD+ is the substrate that makes all of it work.
And here's the problem: you lose roughly half of it by the time you're 50.
I've been following the NAD+ research for years, and what strikes me isn't any single study — it's the convergence. When you have independent research groups across Harvard, the University of New South Wales, Washington University, and dozens of other institutions all arriving at the same conclusion through different experimental approaches, you pay attention. The NAD+ decline hypothesis has gone from fringe to mainstream longevity science in about a decade.
This article covers the biology in real depth — the sirtuin family, the PARP competition model, the precursor debate, and where the human evidence actually stands. NAD+ is a coenzyme essential for over 500 enzymatic reactions, levels drop roughly 50% between ages 30 and 60, and the enzymes that depend on it — sirtuins, PARPs, CD38 — are all competing for a shrinking pool. The animal data is compelling, the human data is promising, and the gap between the two is where honest scientists live.
NAD+ biology: more than an energy molecule
Let me start with what NAD+ actually does, because most summaries stop at "it's important for energy production" and miss the bigger picture.
NAD+ (nicotinamide adenine dinucleotide) exists in two forms: NAD+ (oxidized) and NADH (reduced). Together, they form a redox couple that shuttles electrons in metabolic reactions. In the mitochondria, this electron transport is what drives ATP production — the energy currency of every cell. Without adequate NAD+, your mitochondria can't produce ATP efficiently, and cellular energy drops.
But here's what makes NAD+ different from other metabolic cofactors: it's also consumed — literally broken apart and used up — by two families of enzymes that are critical to aging.
NAD+ as substrate, not just cofactor
Most vitamins and cofactors participate in reactions but aren't destroyed in the process. They catalyze a reaction and emerge intact. NAD+ is different. When sirtuins use NAD+, they cleave it. When PARPs use NAD+, they cleave it. When CD38 uses NAD+, it cleaves it. Each reaction consumes one molecule of NAD+ and produces nicotinamide as a byproduct.
This means NAD+ levels aren't just about production — they're about the balance between synthesis and consumption. As you age, consumption goes up (more DNA damage, more inflammation, more CD38 activity) while synthesis stays flat or declines. The result is the steady erosion of NAD+ that researchers have documented across multiple tissues and species.
For my own research protocols, I source NAD+ through Solira Peptides — third-party tested, pharmaceutical-grade purity on every batch.
The sirtuin family: seven enzymes, seven jobs
Sirtuins are often called "longevity enzymes" or "anti-aging genes," and while that's an oversimplification, it's not wrong in direction. There are seven mammalian sirtuins (SIRT1 through SIRT7), each with distinct cellular locations and functions. All of them require NAD+ to function.
SIRT1: the master metabolic regulator
SIRT1 is the most studied sirtuin and the one most people think of when they hear the word. It lives in the nucleus and cytoplasm and deacetylates proteins involved in metabolism, inflammation, and stress resistance.
SIRT1 activates PGC-1alpha, the master regulator of mitochondrial biogenesis — literally the signal to build more mitochondria. It deacetylates p53, modulating the cellular stress response and apoptosis, and suppresses NF-kB, the central inflammatory transcription factor. It also regulates FOXO transcription factors controlling antioxidant defense and autophagy, and modulates circadian rhythm through interaction with the CLOCK/BMAL1 complex.
SIRT1 is the sirtuin that responds to caloric restriction. When you fast or restrict calories, NAD+ levels in certain tissues rise, SIRT1 activity increases, and you get many of the metabolic benefits associated with caloric restriction. This is the mechanistic basis for the hypothesis that NAD+ restoration could mimic some effects of caloric restriction without the actual restriction.
SIRT2: cytoskeletal integrity and cell division
SIRT2 is primarily cytoplasmic and regulates the cell cycle, cytoskeletal dynamics, and myelination in the nervous system. It deacetylates alpha-tubulin, which is critical for proper cell division and intracellular transport. Dysregulation of SIRT2 has been linked to neurodegenerative diseases, though the relationship is complex — both too much and too little SIRT2 activity appear problematic.
SIRT3: the mitochondrial guardian
SIRT3 is the major mitochondrial deacetylase, and it's arguably the sirtuin most directly relevant to aging. It lives inside the mitochondria and regulates virtually every major metabolic pathway there.
SIRT3 activates isocitrate dehydrogenase 2 (IDH2) and superoxide dismutase 2 (SOD2), providing direct antioxidant defense within mitochondria. It regulates fatty acid oxidation enzymes, influencing how efficiently mitochondria burn fat, and modulates the electron transport chain complexes that affect ATP production efficiency.
SIRT3 knockout mice develop accelerated features of metabolic syndrome. SIRT3 overexpression in animal models extends lifespan. The connection between SIRT3 activity, NAD+ availability, and mitochondrial health is one of the strongest mechanistic links in aging biology.
SIRT4 and SIRT5: the other mitochondrial sirtuins
SIRT4 regulates glutamate metabolism and insulin secretion. It's less studied than SIRT3 but plays a role in how mitochondria handle amino acids and respond to metabolic stress.
SIRT5 is a desuccinylase and demalonylase — it removes chemical modifications from proteins that the other sirtuins don't touch. It regulates urea cycle function, fatty acid oxidation, and ketogenesis. Emerging research suggests SIRT5 may play a role in cancer metabolism and cardiac function.
SIRT6: the DNA repair specialist
SIRT6 sits on chromatin and plays a direct role in DNA repair, particularly double-strand break repair and base excision repair. It also regulates telomere maintenance and suppresses genomic instability.
Here's a striking finding: overexpression of SIRT6 in mice extends lifespan by approximately 15-27%. Conversely, SIRT6 knockout mice develop severe premature aging and die within weeks. Of all the sirtuins, SIRT6 may have the most direct connection to lifespan determination.
SIRT6 also suppresses retrotransposon activity — the "jumping genes" that become more active with age and contribute to genomic instability. This is an increasingly recognized feature of aging, and SIRT6's role in keeping these genetic elements suppressed is a growing area of research.
SIRT7: the ribosomal regulator
SIRT7 is found in the nucleolus, where it regulates ribosomal RNA transcription and the cellular stress response. It plays a role in protein synthesis homeostasis and has been linked to cardiac function — SIRT7 knockout mice develop heart hypertrophy and inflammatory cardiomyopathy.
The unified sirtuin narrative
The seven sirtuins collectively regulate metabolism, DNA repair, inflammation, mitochondrial function, protein homeostasis, and stress resistance. All of them require NAD+. As NAD+ declines, all seven lose activity simultaneously. This isn't one pathway failing — it's a coordinated decline across every major protective mechanism in the cell.
This is why NAD+ restoration is such a compelling target. You're not fixing one thing — you're potentially restoring the substrate for an entire family of protective enzymes.
The PARP competition model
Here's where the math gets uncomfortable. PARPs (poly-ADP-ribose polymerases) are your cell's primary DNA repair enzymes. PARP1, the most active family member, is responsible for detecting and initiating repair of single-strand DNA breaks. Every time it fixes a break, it consumes NAD+.
DNA damage accumulates with age. UV radiation, oxidative stress, environmental toxins, and even normal metabolic byproducts damage your DNA constantly. Young cells handle this efficiently — they have plenty of NAD+, PARPs fix the damage, and enough NAD+ remains for sirtuins to do their job.
But as you age, DNA damage increases while PARP activity ramps up to deal with it. That increased PARP activity consumes more NAD+, leaving less for sirtuins. Reduced sirtuin activity means less mitochondrial maintenance, more inflammation, and worse DNA repair coordination — which creates even more cellular stress and more DNA damage. The cycle feeds itself.
This is the PARP competition model, and it explains why NAD+ decline has such disproportionate effects. It's not a linear relationship — it's a vicious cycle where declining NAD+ simultaneously reduces repair capacity and protective signaling.
David Sinclair's group at Harvard demonstrated this directly: in aged mice with elevated PARP activity, sirtuins were effectively outcompeted for NAD+. Restoring NAD+ levels using NMN reactivated sirtuin function and reversed several aging markers in muscle and brain tissue.
CD38: the real NAD+ destroyer
For years, the assumption was that NAD+ decline was primarily about reduced production — the enzymes that synthesize NAD+ slow down with age. But research over the past decade has identified a more significant culprit: CD38.
CD38 is an ectoenzyme found on the surface of immune cells that degrades NAD+ with extraordinary efficiency. One molecule of CD38 can destroy approximately 100 molecules of NAD+ per second. It uses NAD+ to produce cyclic ADP-ribose, which functions in calcium signaling.
Here's the critical finding: CD38 expression increases dramatically with age, driven primarily by chronic low-grade inflammation — the "inflammaging" that characterizes the aging process. As senescent cells accumulate and chronic inflammatory signaling rises, CD38 expression on immune cells goes up, and NAD+ gets consumed faster than it can be produced.
Research published in Nature Metabolism showed that CD38 knockout mice maintain youthful NAD+ levels into old age and are protected from age-related metabolic decline. This suggests that CD38 isn't just correlated with NAD+ loss — it's a primary driver.
This has led to interest in CD38 inhibitors as a complementary approach to NAD+ restoration. Rather than just flooding the system with more NAD+ or its precursors, blocking the enzyme that's destroying it could be equally or more effective. Compounds like apigenin (found in parsley and chamomile), quercetin, and the more specific research compound 78c have shown CD38 inhibitory activity in preclinical models. The human data on CD38 inhibition for longevity purposes is essentially non-existent at this point — a promising hypothesis waiting for clinical testing.
Delivery routes: IV vs. subcutaneous vs. oral
One of the most practical questions in NAD+ research is how to get it into cells effectively. The delivery route matters enormously because NAD+ itself doesn't survive oral administration well — it's a large, charged molecule that's rapidly degraded in the gut.
Intravenous (IV) NAD+
IV administration delivers NAD+ directly into the bloodstream, bypassing the gastrointestinal tract entirely. This achieves the highest peak blood levels and is the route used in many clinical settings. Research formulations for IV use are typically concentrated at 500mg (ref: NJ500).
The advantages are straightforward: high bioavailability, rapid onset, and predictable dosing. The disadvantages are also clear — it requires clinical administration, takes 1-4 hours per session, and can cause nausea, chest tightness, and cramping during infusion, likely related to the rapid NAD+ flux.
Subcutaneous injection
Subcutaneous NAD+ delivery is newer in the research setting and offers a middle ground between IV and oral routes. The NAD+ is injected just below the skin, absorbed more slowly than IV but more completely than oral. This route avoids the GI degradation problem while allowing self-administration.
The pharmacokinetic profile differs from IV — lower peak levels but more sustained elevation. Some researchers prefer this, arguing that a steady-state elevation of NAD+ is more physiologically relevant than a brief spike.
Oral precursors: NMN and NR
Since NAD+ itself has poor oral bioavailability, the oral approach uses precursors — molecules that the body converts into NAD+ after absorption. The two leading candidates are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside).
The NMN vs. NR vs. direct NAD+ debate
This is one of the most debated topics in longevity science, and I want to give you the honest landscape rather than advocate for any single approach.
NMN (nicotinamide mononucleotide)
NMN is David Sinclair's preferred precursor, and his lab at Harvard has produced much of the foundational research. NMN is one enzymatic step away from NAD+ — the enzyme NMNAT converts NMN directly to NAD+. In mouse studies, oral NMN supplementation raises NAD+ levels in multiple tissues and reverses several age-related markers.
The key human study: a 2022 clinical trial published in Science showed that 250mg of NMN daily for 12 weeks increased NAD+ metabolite levels in blood and improved muscle insulin sensitivity in prediabetic women. The effect was modest but measurable, and it was the first rigorous demonstration that oral NMN can affect NAD+ metabolism in humans.
A question that persisted for years was whether NMN could even survive intestinal absorption. In 2019, the discovery of the Slc12a8 transporter — a protein on intestinal cells that transports NMN directly into the bloodstream — provided a potential mechanism, though this finding has been debated.
NR (nicotinamide riboside)
NR is two enzymatic steps from NAD+ — it must first be converted to NMN by the enzyme NRK1/NRK2, and then NMN is converted to NAD+ by NMNAT. NR is commercially available as Niagen (marketed by ChromaDex) and has been through several human clinical trials.
The human data for NR is actually more extensive than for NMN. Multiple trials have shown that NR supplementation at 250-1000mg daily increases blood NAD+ levels by 40-90%, is well-tolerated, and produces measurable changes in NAD+ metabolomics. A 2018 trial in Nature Communications demonstrated dose-dependent NAD+ elevation in healthy older adults.
The gap between raising NAD+ levels in blood and demonstrating meaningful clinical outcomes in humans remains largely unbridged, though. We can measure the NAD+ going up. What we can't yet prove in rigorous human trials is that this translates to the lifespan and healthspan benefits seen in mice.
Direct NAD+ (injectable)
Direct administration of NAD+ bypasses the entire precursor conversion pathway. The molecule doesn't need to be absorbed orally, doesn't need enzymatic conversion, and reaches the bloodstream intact when given IV or subcutaneously. This is the most direct approach pharmacokinetically.
The trade-off is route of administration — injections are less convenient than oral supplements, and the cost per dose is typically higher. But for research purposes, direct NAD+ allows precise control over dosing and eliminates variables related to precursor conversion efficiency.
The Sinclair lab and the Harvard NAD+ research
No discussion of NAD+ in longevity science is complete without addressing David Sinclair's contributions. His lab at Harvard Medical School has been arguably the most influential in establishing NAD+ as a central aging target.
In 2013, his group published a landmark paper in Cell demonstrating that raising NAD+ levels with NMN in aged mice reversed mitochondrial dysfunction in skeletal muscle. The mitochondrial function of 22-month-old mice (roughly equivalent to 60 human years) became indistinguishable from 6-month-old mice after just one week of treatment.
A 2017 paper in Science showed that NAD+ restoration via NMN improved DNA repair capacity in aged mice and protected against radiation-induced DNA damage — research that attracted interest from NASA for potential astronaut protection. In 2018, a Cell paper demonstrated that NMN treatment improved blood flow and exercise capacity in aged mice by promoting angiogenesis through a SIRT1-dependent mechanism. And in 2020, Cell Metabolism published their work extending NAD+ findings to brain aging, showing NMN treatment improved cognitive function and neurovascular health in aged mice.
The criticism of Sinclair's work — and he's open about this — is that the mouse data is far ahead of the human data. Mice are not humans. Doses that work in mice don't always translate. And Sinclair has been more publicly enthusiastic about NAD+ supplementation than some of his colleagues think the human evidence warrants.
That's a fair criticism. But the biological logic is sound, the mechanistic data is robust across multiple independent labs, and the early human data points in the right direction. We just need more of it.
Combination approaches: NAD+ in the longevity stack
One of the most active areas of longevity research is how NAD+ interacts with other interventions.
Resveratrol, the original sirtuin activator, works by making SIRT1 more efficient — it can do more work per molecule of NAD+. The hypothesis is that resveratrol plus NAD+ restoration creates a synergy: more fuel (NAD+) plus a more efficient engine (resveratrol-activated SIRT1). Sinclair has proposed this combination based on his mouse data, though human evidence for the combination is limited.
Rapamycin inhibits mTOR, the growth-signaling pathway that, when chronically active, accelerates aging. NAD+ and rapamycin target different but complementary pathways — NAD+ supports repair and maintenance through sirtuins, while rapamycin suppresses growth signals that compete with repair. There's preclinical rationale for combining them, but no human combination data.
Metformin, the diabetes drug that activates AMPK, may function as a partial NAD+ booster in addition to its direct metabolic effects. AMPK activation can increase NAD+ levels through downstream effects on NAMPT, the rate-limiting enzyme in NAD+ salvage synthesis. The TAME trial (Targeting Aging with Metformin) is testing metformin's longevity effects in a large human cohort.
CD38 inhibitors represent a complementary approach — blocking the enzyme that destroys NAD+ rather than just supplementing precursors. The combination of precursor supplementation plus CD38 inhibition could theoretically be more effective than either alone. This remains theoretical in humans.
Where the human evidence actually stands
I want to be straightforward about this because I think the longevity field sometimes overpromises.
We know for certain that NAD+ levels decline with age — well-documented in blood and tissue samples. We know oral NMN and NR can raise blood NAD+ levels, confirmed by multiple clinical trials. Direct IV/subcutaneous NAD+ achieves higher tissue levels than oral precursors. And these interventions are generally well-tolerated.
We have suggestive evidence that NMN may improve muscle insulin sensitivity (one clinical trial, modest effect), that NR may improve some inflammatory markers in older adults (small studies), and that IV NAD+ produces subjective improvements in energy and cognition (clinical observations, limited controlled data).
What we don't have yet: proof that raising NAD+ extends lifespan or healthspan in any measurable way. No large-scale, long-term randomized trials with hard clinical endpoints. No clear evidence that one delivery route or precursor is definitively superior. No optimal dosing established through dose-response studies.
The gap between the animal data and the human data is real. In mice, NAD+ restoration reverses aging markers in muscle, brain, vasculature, and metabolism. In humans, we can show that NAD+ goes up in the blood. The translation from one to the other is the central challenge facing the field.
Does this mean NAD+ restoration is pointless? No. The biological logic is sound, the animal data is robust, and the early human data is directionally positive. But anyone taking NAD+ precursors or receiving NAD+ infusions is making a bet — a reasonable, science-informed bet — that the human data will eventually catch up with the animal data. I think the odds favor that bet, but honesty requires acknowledging the uncertainty.
Frequently asked questions
How quickly do NAD+ levels decline with age?
The decline begins around age 30 and accelerates through middle age. By approximately 50, tissue NAD+ levels are roughly half of what they were at peak. The decline is driven primarily by increasing CD38 expression related to chronic inflammation, increased PARP activity from accumulated DNA damage, and declining NAMPT. It's not uniform across tissues — some organs, like the brain and liver, may be more affected than others.
Is NMN or NR better for raising NAD+?
There is no consensus. NMN is one enzymatic step closer to NAD+ (it requires only NMNAT for conversion), while NR requires two steps. In theory, NMN should be more efficient. In practice, both raise blood NAD+ levels in human studies, and no head-to-head human trial has compared them at equivalent doses with the same endpoints. NR has more published human clinical trial data; NMN has stronger advocacy from the Sinclair lab.
What about IV NAD+ compared to oral supplements?
IV NAD+ achieves higher peak blood levels than any oral precursor, avoids GI degradation, and doesn't require enzymatic conversion. The trade-offs are inconvenience, cost, and acute side effects during infusion like nausea, flushing, and cramping. Subcutaneous injection offers a middle ground. Oral precursors are the most convenient but have the most variable absorption and conversion.
Can I take NAD+ precursors with other supplements?
There are no known dangerous interactions between NAD+ precursors and common supplements. The theoretical synergy with resveratrol (SIRT1 activator), quercetin (potential CD38 inhibitor), and other compounds has some preclinical support. But "no known interaction" is not the same as "proven safe in combination" — the combination data in humans is virtually non-existent.
How long until effects show up from NAD+ restoration?
This depends on the route and the outcome you're measuring. IV NAD+ produces subjective effects like energy and mental clarity within hours in many recipients — though placebo effects are real and haven't been adequately controlled for in most settings. Oral precursors take days to weeks to raise blood NAD+ levels measurably. Whether either approach produces meaningful long-term health benefits is an open question that may take years of ongoing research to answer.
Is the NAD+ decline a cause of aging or a consequence?
Probably both. The decline is driven by aging-related processes (inflammation, DNA damage, senescent cell accumulation), which makes it partly a consequence. But the decline also drives further aging-related deterioration (reduced sirtuin activity, impaired DNA repair, mitochondrial dysfunction), which makes it partly a cause. This bidirectional relationship is what makes NAD+ such an interesting intervention target — by restoring NAD+ levels, you may be able to interrupt a self-reinforcing cycle of decline, even if you're not addressing the original trigger.